This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

IBRANCE® Case Studies

IBRANCE® Case Study - A Patient with significant Visceral Metastases

Dr Mark Verrill
​​​​​​​Head of Oncology and Deputy Team Lead Clinician
For Breast Cancer North of England Cancer Network

IBRANCE® Case Study - A Second Line Patient

Dr Mark Verrill
​​​​​​​Head of Oncology and Deputy Team Lead Clinician
For Breast Cancer North of England Cancer Network

IBRANCE® Case Study - A Pre-Menopausal Patient

Dr Mark Verrill
​​​​​​​Head of Oncology and Deputy Team Lead Clinician
For Breast Cancer North of England Cancer Network

IBRANCE® Case Study - An Elderly Patient with Bone Metastases

Dr Mark Verrill
​​​​​​​Head of Oncology and Deputy Team Lead Clinician
For Breast Cancer North of England Cancer Network


​​​​​​​Pfizer's Commitment to the Oncology Community through the COVID-19 Pandemic

Pfizer's commitment to the Oncology Community through the COVID-19 Pandemic

Dr Erling Donnelly
Head of Oncology, Pfizer UK


 ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

PP-IBR-GBR-3734. July 2021

Resources

  • Resources to assist you and your patients
  • IBRANCE® Resources
  • Adapting Breast Cancer Care during COVID-19 Pandemic
  • Patient Resources

Indication

  • IBRANCE® is indicated for the treatment of HR+ HER2- locally advanced or metastatic breast cancer:
       - In combination with an aromatase inhibitor; or
    ​​​​​​​   - In combination with fulvestrant in women who have received prior ET

    In pre- or perimenopausal women, the ET should be combined with a LHRH agonist

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No